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Summary Efforts to assess the efficacy of new therapies in the treatment of acute
exacerbations of chronic obstructive pulmonary disease (COPD) have been hampered
by the lack of a widely agreed and consistently used definition. A variety of definitions
have been used in clinical studies, based on changes in patient symptoms or the
requirement for antibiotic therapy, oral steroids or hospitalisation. To date, none of
these definitions have been assessed in detail for their reliability, responsiveness and
validity determined. Considerable heterogeneity in the aetiology and manifestation
of COPD exacerbations makes identification and quantification of defining symptoms
extremely difficult. New approaches are therefore being sought with a view to
identifying a serum or tissue marker that can be used as a valuable diagnostic tool.
Improvements in data recording will also contribute to the accuracy of data retrieval
and assessment. If we are to progress to a level of sophistication seen in the diagnosis
and management of other diseases, it is evident that considerable research efforts
will be required to improve our understanding of COPD exacerbations and develop a
standard definition for these events, thereby facilitating the assessment of
therapeutic approaches.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Recognition of significant unmet need in the
treatment of chronic obstructive pulmonary dis-
ease (COPD) has led to considerable research
activity in the last decade in an attempt to increase
understanding of the pathophysiology of this com-
plex condition and improve therapeutic options. An
important feature of COPD is the periods of
worsening of symptoms, commonly called an ‘ex-
acerbation’. Exacerbations are a common occur-
rence for many COPD patients and contribute
greatly to the increased morbidity and diminished
health-related quality of life (HRQOL) that are
characteristic of severe COPD. Exacerbation fre-
quency and severity increase with advancing dis-
ease, resulting in reduced health status, frequent
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hospital admissions and increased healthcare
costs.1,2 Exacerbations can also have a significant
impact on the patient’s long-term condition;
evidence is accumulating to suggest that repeated
episodes result in faster decline in lung function,
thereby contributing to disease progression.3,4 In
addition, functional status and HRQOL can remain
impaired for some time following an exacerba-
tion.5,6
Efforts aimed at improving treatment options
have been hampered by a fundamental problem:
the lack of a consistent and widely accepted
definition of an exacerbation with which to
evaluate and compare therapeutic interventions.
In this paper, the problems associated with estab-
lishing a standardized definition of COPD exacer-
bations are reviewed and key objectives and future
directions are discussed.
The heterogeneity of COPD
exacerbations
While understanding of the nature and initiating
factors of exacerbations has increased greatly in
recent years, these advances have served to
confirm the complexity of the condition and
heterogeneous nature of exacerbations, which vary
greatly from person to person.7 Patients can
experience a wide range of symptoms during an
exacerbation, the most common being breathless-
ness, wheeze, chest tightness, increased cough,
fever and changes in sputum color or volume.8 A
number of non-specific symptoms may also be
present, such as general malaise, insomnia, fati-
gue, depression and confusion.8 Significant, but
small, falls in PEF, FEV1 and FVC (indicative of
airway narrowing) have also been observed during
an exacerbation. 5 While these symptoms and
measurements are frequently associated with
periods of exacerbation, no diagnostic symptom
or group of symptoms have been identified and the
clinical presentation of individual patients varies
appreciably.
Many exacerbations are thought to arise as a
result of bacterial infection, although the type of
infection is often unclear. A wide variety of
bacteria can be cultured from stable COPD
patients, which may not result directly in an
exacerbation, but could be responsible for stimu-
lating airway inflammation. Indeed, a relationship
between lower airway bacterial colonization and
exacerbation frequency has recently been estab-
lished.9 Haemophilus influenzae, Moraxella catar-
rhalis and Streptococcus pneumoniae are the most
common bacteria found in the sputum of patients
during an acute exacerbation.10,11 In addition,
atypical pathogens such as Chlamydia pneumoniae
may account for up to 10% of exacerbations.1,12
Viral infection, principally rhinovirus and influenza
virus, is also likely to play a significant role in the
development of an exacerbation, accounting for
around 30% of episodes.13,14 A recent study has
demonstrated viral respiratory pathogens in 56% of
patients with acute exacerbations requiring hospi-
talization, suggesting that the contribution of these
pathogens is generally underestimated.15 In many
cases, however, there is no evidence of infection
and environmental triggers or comorbidities are
thought to be the initiating factors.1,8 It is likely
that the variety of underlying events contributes
greatly to the heterogeneity of symptoms.
Current outpatient treatment of exacerbations is
largely empirical, comprising a combination of
bronchodilators, antibiotics and corticosteroids.1,8
The varied etiology and presentation of exacerba-
tions may account for the fact that each of these
treatment approaches, as well as placebo, have
been associated with improved resolution of symp-
toms. Hospital assessment or admission is indicated
if symptoms are severe, if the patient is hypoxemic
or if physical signs such as cyanosis or peripheral
edema develop. In such cases, the need for oxygen
therapy is unquestioned and non-invasive positive-
pressure ventilation may be considered in selected
patients. This approach has been shown to reduce
the requirement for invasive ventilation and im-
prove survival.1,16,17
The need for greater understanding of the many
types of COPD exacerbation is increasingly appar-
ent. Not only will this knowledge provide insights
into why some patients experience frequent ex-
acerbations while in others such events are rare,
but also better definition and understanding may
allow a tailored treatment approach with potential
for increased management success.
Development of COPD exacerbation
criteria
Since Fletcher first described ‘chest episodes’ in
1976, interest and research activity in the field of
COPD have increased steadily.18 The absence of
agreed criteria for the diagnosis of COPD exacer-
bations has necessitated the development of work-
ing definitions with which to assess the patient’s
condition and evaluate the success of therapeutic
intervention. From such research emerged the
classic definition of Anthonisen et al.19 which
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describes three levels of exacerbation based on
patient symptomatology (Table 1). This definition
was, however, developed prospectively for analy-
tical purposes only, not for differences in approach
to management. This description remains the most
commonly referenced of all definitions and has
formed the basis of many subsequent criteria.
It is apparent that the primary objective of a
study will influence the approach to collection of
exacerbation data. For example, the study by
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Table 1 Definitions of exacerbation used in interventional studies.
Study (author and
intervention)
Definition Basis of definition
Event Symptom
Anthonisen et al., 1987;
antibiotic therapy19
Type 1 The occurrence of increased dyspnea,
sputum volume and sputum purulence
F O
Type 2 When two of these symptoms were
present
Type 3 When one of the three symptoms was
present in addition to at least one of the
following:
upper respiratory infection within the past 5
days
fever without other cause
increased wheezing or cough
increase in respiratory rate or heart rate by
20% as compared with baseline
Thompson et al., 1996; oral
prednisone40
Subjective worsening of chronic baseline
dyspnea or cough for more than 24 hours
duration, necessitating a hospital visit; 425%
increase in inhaled b-agonist use for more
than 24 h or an increase in sputum production
(more than one-fourth cup per day over
baseline) and/or purulence (more than 25
neutrophils/field)
O O
Niewoehner et al., 1999
(SCCOPE study); systemic
glucocorticoids39
Hospital admission with clinical diagnosis of
exacerbation
O F
Mahler et al., 1999;
salmeterol41
Worsening of symptoms F O
Vestbo et al., 1999;
(Copenhagen City study)
budesonide42
More cough and phlegm than usual F O
Burge et al., 2000; ISOLDE
study of fluticasone43
Worsening of respiratory symptoms that
required treatment with oral corticosteroids
or antibiotics or both, as judged by the
general practitioner (specific symptom
criteria not used)
O F
Woolhouse et al., 2001;
fluticasone or antibiotic44
One or more of: F O
increased dyspnea
increased sputum volume
change in purulence
Cazzola et al., 2001;
formoterol45
Sustained worsening of the patient’s condition
from the stable state and beyond normal day-
to-day variations necessitating a change in
regular medication
O F
Compton et al., 2001;
cilomilast46
(Definition not described) F F
Vincken et al., 2002/Casaburi
et al., 2002; tiotropium47,48
A complex of respiratory events (i.e. cough,
wheezing, dyspnea or sputum production)
lasting 43 days
F O
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Fletcher18 was an epidemiological assessment;
exacerbations were not the focus. The primary
outcome of the Anthonisen study, however, was the
effect of antibiotics on exacerbations.19 Seemungal
et al.20 in the East London cohort study, have
investigated the effect of exacerbations on
HRQOL and have used a modified version of the
Anthonisen definition. The key point of difference
in this study is that rather than recording symptoms
at any one time, this group aimed to capture a
change from the preceding day and return to
stable disease following an exacerbation; the
study sought to collect group data rather than
track individuals. Not surprisingly, such different
approaches result in outcomes that are difficult to
compare.
In order to clarify best practice in the diagnosis
and treatment of COPD, a number of guidelines
were developed in the mid-1990s by professional
bodies worldwide.21–23 While these publications
recognize that exacerbations are difficult to define
and that the pathogenesis is poorly understood,
each seeks to provide general descriptions of an
exacerbation. Although they vary somewhat, each
is founded on identifying a worsening of the
previous stable state based on reporting of symp-
toms (primarily dyspnea, sputum volume and
sputum purulence). Many attempts to provide a
better working definition have since been made,
ranging from simple specifications aimed at captur-
ing a change from the normal situation (e.g. the
development of new symptoms with sputum pro-
duction that led to a consultation with the GP)24 to
more complex definitions that attempt to provide a
more descriptive approach (e.g. for at least 2
consecutive days, either two or more of three
major symptoms or any one major symptom
together with a minor symptom).20
In recent years, some attempts have been made
to redress the inconsistency in definition with
initiatives such as the 1999 Aspen workshop.25
The working party of international experts devel-
oped a new definition of exacerbations: ‘A sus-
tained worsening of the patient’s condition, from
the stable state and beyond normal day-to-day
variations, that is acute in onset and necessitates a
change in regular medication in a patient with
underlying COPD.’ While the rationale behind the
Aspen consensus statement is sound, its application
as a practical tool is limited in a number of
respects. How can we define a sustained worsening?
The authors explain this as worsening of symptoms
for longer than 24 h, but also suggest that the
definition should not exclude some patients with
acute presentation. This also raises the question of
how worsening should be assessed; the authors
acknowledge that this is imprecise because of the
lack of established clinical markers, signs and
symptoms. The recommendations also contain no
direction on how a change from stable state should
be determined. The requirements of a definition
that is intended for use in the evaluation of
therapeutic intervention may differ from those
intended to identify an exacerbation in day-to-day
clinical practice. Future efforts to describe a
standard definition will therefore need to consider
the application as a fundamental part of the
development.
It would appear that increased interest in COPD
exacerbations and continued attempts to describe
this complex condition have produced only greater
disparity and a wider range of definitions. The fact
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Table 1 (continued)
Study (author and
intervention)
Definition Basis of definition
Event Symptom
Maltais et al., 2002;
budesonide49
Requiring hospitalization. Exacerbation
defined as increased breathlessness
O O
Mahler et al., 2002;
Salmeterol/fluticasone
combination50
Defined by treatment (mild¼ increased use of
Ventolin; moderate¼ use of either oral
antibiotics and/or corticosteroids;
severe¼ hospitalization)
O F
Szafranski et al., 2003;
Combined budesonide and
formoterol51
Severe: requirement for oral steroids and/or
antibiotics and/or hospitalization due to
respiratory symptoms
O F
Mild: a day with X4 inhalations of reliever
medication above the mean run-in use
Calverley et al., 2003;
Combined salmeterol and
fluticasone52
Worsening of COPD symptoms that required
treatment with antibiotics, oral
corticosteroids, or both
O F
102 R. Pauwels et al.
that considerable effort and focus has not resulted
in greater agreement and standardization may
reflect the fundamental difficulty in defining and
measuring such a heterogeneous condition.
Symptom versus event-based definitions
The wealth of definitions employed to date can be
categorized broadly on the basis of their description
of patient symptoms (symptom-based definitions) or
definitive events (event-based definitions).
Symptom-based definitions
Symptom-based definitions represent the most
commonly adopted approach, relying primarily on
worsening of dyspnea and increases in sputum
volume or purulence. While these symptoms are
commonly seen during an exacerbation, one study
has shown that only 64% of exacerbations were
associated with increased dyspnea, 42% with
increased sputum volume and 35% with purulent
sputum, exacerbations being defined on the basis of
a modified Anthonisen criteria.5
There are a number of advantages and disadvan-
tages to the use of a symptom-based definition.
Symptoms are of fundamental importance and are
the primary concern of the patient; it is generally a
change in symptoms that prompts contact with
healthcare professionals. Assessment of patient
symptoms and subsequent improvement with ther-
apy is therefore a fundamental consideration for
both patient and physician. Identification of a
standardized symptom-based definition is likely to
be complicated by the highly varied nature of COPD
and its exacerbations. As patient symptomatology
varies greatly, and an absolute level of dyspnea or
sputum volume cannot be described as diagnostic,
a subjective assessment of ‘worsening’ is therefore
required. In this case, it is a matter of some debate
as to who is best placed to make this judgment: the
patient or the doctor?
While some scales for symptom assessment do
exist, and these can be used as a basis for future
development, the validity of current scales and
their sensitivity to change have not been estab-
lished and validating a new scale would be a
significant undertaking. The most common ap-
proach to capturing symptom change over time
requires the use of a paper-based diary card. This
approach is increasingly controversial as it is
associated with a number of intrinsic disadvan-
tages, the most problematic of which is extremely
poor adherence to protocol instructions, and data
validity issues arising from retrospective record
entry.26
Validation of the magnitude of changes in
symptom scales is badly needed. This should be
done by comparing the exacerbation-related
changes to random variations outside clinically
defined exacerbation periods. More importantly,
the symptoms in any symptom scale should be
related to the efficacy of a therapeutic interven-
tion. The Anthonisen study established the need to
fulfil three clinical criteria (increased dyspnea,
increased sputum volume and the presence of
purulent sputum) for an antibiotic treatment to
be effective. In the same way, the magnitude of
changes in breathlessness, coughing, etc. could be
validated by relating them to the effectiveness of a
course of systemic corticosteroids. This approach
would not only help us to define relevant changes in
symptom scales but would also help us to define
exacerbations that require treatment with sys-
temic corticosteroids.
Event-based definitions
Event-based definitions have been increasingly
used in an attempt to circumvent the problems
associated with identifying and defining symptoms
or groups of symptoms, and simply capture all
patients whose condition has changed enough to
require hospitalization or a change of treatment
(generally a requirement for oral steroids or
antibiotics). Classification of exacerbations based
on events offers a straightforward approach and is
therefore widely used in clinical trials. Event-based
criteria do, however, require a sequence of
decision-making involving both the patient and
the doctor. As it has been demonstrated that only
50% of exacerbations (defined according to mod-
ified Anthonisen criteria) are reported to a physi-
cian),5,20 this method captures significantly fewer
episodes than symptom-based definitions and is
likely to select a distinct patient group. However, in
the absence of definitive signs and symptoms on
which to base a diagnosis, event-based definitions
currently represent the most unambiguous and
practical approach to clearly identifying episodes
of exacerbation. As patient burden is largely
associated with the symptoms they experience,
an event-based definition may lack the ability to
describe the events of most importance to the
patients. Further research aimed at identifying key
symptoms, which correlate with exacerbations
identified by event-based criteria, could therefore
be of great utility.
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Defining study populations in the clinical
evaluation of therapeutic interventions
Many symptom- and event-based definitions and
criteria have been adopted in interventional
studies (Table 1). These have arisen from the need
to establish criteria by which to select patients for
inclusion and the absence of a clear and widely
accepted definition. Trials conducted today still use
a wide variety of definitions by which treatment
success is judged, with increasing focus on event-
based definitions. There is, however, no evidence
of improving consistency and many publications
feature inadequate descriptions of inclusion criter-
ia. While each is intended to meet a specific need
and highlight an appropriate endpoint, the lack of a
consistent definition of exacerbation makes com-
parison of study findings and treatment effect
virtually impossible.
With the emergence of a number of drugs
designed or developed specifically to treat COPD
and associated exacerbations, the absence of a
uniform definition has become a significant is-
sue.25,27 The choice of definition can significantly
affect study outcomes, with varying criteria likely
to result in different levels of demonstrated
treatment success. The latest set of guidelines
developed by the NHLBI/WHO Global Initiative for
Chronic Obstructive Lung Disease (GOLD), while
unable to provide greater insight or consistency of
definition, do highlight the need for an outcome
measure as an important future goal.
A new approach to defining COPD
exacerbations
Despite some effort to describe COPD exacerba-
tions and their associated symptoms, the continu-
ing lack of a widely accepted and reproducible
definition highlights the fact that attempting to
define and re-define exacerbations based on cur-
rent levels of understanding may not be possible. It
is therefore likely that we need to seek success
through an alternative strategy, and approaches in
other disease areas may provide a useful template.
In cardiology, approaches to the diagnosis and
treatment of myocardial infarction are well devel-
oped and universally adopted. It is therefore
possible that success in the diagnosis and manage-
ment of COPD exacerbations will need to follow a
similar development course, whereby symptoms
that define events are confirmed by an accompany-
ing sign, which is in turn related to a biological
mechanism. In order to achieve this goal, a great
deal of further research will be required. Symptoms
most commonly associated with exacerbations are
increased breathlessness, increased sputum pro-
duction or purulence, cough, wheeze and fever.27
Description of key diagnostic symptoms will, how-
ever, need to be clearly defined and standardized
and the method by which they are determined
validated. A definitive sign is yet to be identified;
respiratory rate has been suggested but little
research has focused on this area. While descrip-
tion of diagnostic signs and symptoms would
require concerted research effort, it does seem
an unattainable goal. Description of a practical and
widely applicable biological marker, however,
remains elusive.
Biological markers of exacerbation
Only a handful of studies describing changes in
biological markers during exacerbations have been
described in the literature to date, although
increasing recognition of their potential utility
may spark further research in this field. Many of
the studies to date have focused on markers of
inflammation. Once again, the heterogeneity of
COPD exacerbations presents a problem in pursuing
such biomarkers, as inflammation may not be
common to all exacerbations.24
Serum IL-6 levels have been shown to increase
during exacerbations, leading to increased plasma
fibrinogen levels.28,29 It is likely, however, that this
indicator is strongly correlated with viral infection
and may therefore not represent a global marker.28
Exacerbations have also been associated with
increased urinary excretion of isoprostane F2a-III
in hypoxemic patients,30 and increased plasma
levels of the acute-phase reactant C-reactive
protein,31 serum eosinophilic cationic protein and
myeloperoxidase.32 Arterial blood gas analysis may
be a useful indicator of exacerbation severity and
prognosis.
Bronchial biopsies obtained from patients at the
time of an exacerbation have shown marked airway
eosinophilia (with an associated increase in RANTES
expression) and a lesser increase in the number of
neutrophils, activated T-lymphocytes, and TNF-a-
positive cells in the bronchial mucosa.33,34 While
this approach can provide important information on
tissue changes related to an exacerbation, the
invasive nature of the technique limits its applica-
tion, particularly during an exacerbation. Bronch-
eoalveolar lavage (BAL) has proved a useful
alternative providing insights into the inflammatory
nature of exacerbations. Studies of BAL fluid have
shown changes in the cell populations consistent
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with a recruitment of polymorphonuclear leuco-
cytes in the airway lumen.35,36 Observed increases
in levels of granulocyte–macrophage colony-stimu-
lating factor might suggest a role for this cytokine
in the inflammatory processes during exacerba-
tions.35 Less invasive still is the assessment of
induced sputum, which has demonstrated in-
creased IL-6 levels during exacerbations and higher
IL-6 and IL-8 levels in patients with frequent
exacerbations.28,37 Exacerbations classified by spu-
tum color have been shown to differ in the degree
of bronchial and systemic inflammation. Purulent
exacerbations are related to bacterial infection
and are associated with marked inflammation,
increased neutrophilic inflammation and increased
LTB4 concentrations.38 Mucoid exacerbations are,
however, associated with little inflammation and do
not require antibiotic therapy.24
While data from biomarker studies are limited,
these important findings have opened a new avenue
of research towards finding an appropriate marker
for exacerbation.
The challenge ahead
It is clear from this review that there are many
ways to define an exacerbation of COPD. In
practice, it is usually evident to both doctor and
patient when such an event has occurred but the
need to incorporate specific criteria for an exacer-
bation into treatment management plans has
provided a new impetus to try and develop more
objective measures, such as those discussed above.
Additionally, regulators are also concerned with
exacerbations as a potential outcome but require
robust and objective definitions that can be agreed
between healthcare systems before they will
accept that any intervention is effective in modify-
ing this aspect of the disease. Moving from the
simple clinical paradigm to this more desirable
situation, which provides a quantifiable outcome, is
proving to be an extremely difficult task. At
present, there is scepticism that simply counting
the number of medical contacts and therapies
offered may not truly represent the impact of the
disease on the patient’s life. This impression could
be corrected if we were able to demonstrate
changes in an individual’s symptoms, which bore a
clear temporal relationship to their self-reported
events. Progress in this area has already been
made20 but more data across a wider range of
patient severity is still needed. The relative
importance of individual changes in symptoms at
different stages of the disease is less clear and we
still do not know whether symptoms complained of
during an exacerbation in a patient whose FEV1 is
above 50% of predicted differs from those where
lung function is below this value. Likewise, whether
there is any relationship between the type of
symptoms and their impact on the patient’s health
is not resolved. At present, the clearest association
appears to be between the number of events and
the change in health status, but more sophisticated
analysis of this should become possible in the
future.
One attractive approach is to parallel that used
in the management of bronchial asthma and have
patients record their symptoms on a daily diary
card, something which has already been re-
ported.20,28,29,39 As yet, there is no agreement on
what the optimum combination of questions might
be or even whether data should be expressed
relative to a previously defined state, e.g. patient
perception of their usual level of well-being or,
alternatively, to use some external category such as
perceived level of breathlessness or sputum pro-
duction on a Likert scale. If a robust enough
definition of an exacerbation could be established,
it should be possible to interrogate data sets like
this to further understand the nature of the
processes leading to exacerbation and also those
which go on to promote a healthcare contact.
However, our present methods of documenting
information are significantly limited. Most clinical
trials still rely on paper-based diary cards, which
are known to have a compliance as low as 11% and
to be subject to retrospective data entry which
raises significant concerns over the impact of
recall bias on data validity.26 Hopefully, the more
widespread use of electronic data entry will
improve this. This approach has been shown to
increase patient compliance with instructions
dramatically, up to 94% in one instance.26 This
would undoubtedly improve the validity of the data
obtained but would not resolve in itself the subtle
but important issues about which questions are to
be asked.
Despite all these difficulties, the challenge of
exacerbations to the patient and their potentially
preventable nature makes them an appropriate
target for anyone interested in improving the
management of this disease. The recent increased
activity in this area is beginning to bear fruit and
people are becoming aware of the complexity of
these events at both the biological and clinical
level. Modest improvements in data recording
technology and more attention to detail in the
documentation of exacerbations is likely to lead to
significant gains in our understanding, and ulti-
mately in our treatment, of this problem.
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